Table 2. Efficacy of specific sublingual immunotherapy for AD in previous studies.

Study, year	Total number of patients	Age (range, yr)	Types of allergen used	Duration of treatment (mo)	Results
Cadario et al.4 (2007)	86	3~60	HDM	12	A total of 51 patients (51/86, 59.3%) had a significant improvement defined by a SCORAD reduction of >30%.
Pajno et al.10 (2007)	56	5~16	HDM	18	A significant improvement of SCORAD from baseline was seen only in the active group.
Qin et al.3 (2014)	107	18~46	DF	12	A total efficacy rate of 77.78% (35 of 45) was significantly higher than 53.85% (21 of 39) in the control group.
Di Rienzo et al.9 (2014)	27	5~18	HDM	18	A significant improvement of SCORAD from baseline was seen only in the treated group.
Present study	34	9~38	HDM	12	A total of 19 patients (19/23, 82.6%) had a significant improvement defined by a EASI score reduction of >30%.

AD: atopic dermatitis, HDM: house dust mite, SCORAD: SCORing atopic dermatitis, DF: Dermatophagoides farinae, EASI: eczema area and severity index.